Trump says "Drill baby drill" and we explore a market that should benefit greatly from his energy and Ai policies going forward!

 

Pipelines and Energy

Business & Investment Report

Prepared: January 20, 2025
Disclaimer: The following report is for informational purposes only and does not constitute financial or investment advice. Always conduct your own due diligence or consult a licensed professional before making investment decisions.

---

Executive Summary

With President Trump returning to the White House and signaling a renewed focus on traditional energy development—summarized by the slogan “Drill, Baby, Drill”—the U.S. midstream (pipeline) sector stands poised for a potential uptick in natural gas and oil throughput. Easing of permitting processes, expedited infrastructure approvals, and expanded access to federal lands are likely catalysts.

Top Five Pipeline Companies to Watch:

1. Kinder Morgan (NYSE: KMI)
2. Williams Companies (NYSE: WMB)
3. Energy Transfer LP (NYSE: ET)
4. Enterprise Products Partners (NYSE: EPD)
5. ONEOK (NYSE: OKE)

All five have extensive U.S. natural gas infrastructure, strong financial fundamentals, and direct exposure to regions poised for production growth under the current administration’s energy strategy.

---

Market Context

1. Policy Tailwinds:

   • A pro-drilling administration typically reduces regulatory hurdles, possibly accelerating new pipeline projects or expansions.
   • Producers in prolific basins (Permian, Marcellus/Utica, Haynesville, Bakken) could increase output, driving higher demand for pipeline capacity.

2. Natural Gas Dynamics:

   • Rising global Liquefied Natural Gas (LNG) demand (especially in Europe and Asia) supports exports, which boosts midstream volumes.
   • An administration focused on energy independence is likely to encourage increased infrastructure build-out to move resources from wellhead to domestic and international markets.

3. Challenges & Risks:

   • Local and state opposition can still slow or halt pipeline projects despite federal support.
   • Commodity price volatility may affect producers’ capital spending decisions, influencing pipeline volumes.
   • Global economic or geopolitical events could shift demand patterns, affecting throughput.

---

1. Kinder Morgan (NYSE: KMI)

Company Snapshot

• Market Cap (Approx.): $45–50 billion
• Dividend Yield (Approx.): Historically in the 6% range
• Core Operations: 70,000+ miles of natural gas pipelines, plus terminals and storage facilities.

Investment Thesis

• Massive Infrastructure Footprint: Kinder Morgan moves ~40% of U.S. natural gas, making it exceptionally leveraged to any production surge.
• Expansion Projects: Several ongoing or planned capacity expansions (e.g., in the Permian Basin, where associated gas production continues to rise). Under an administration that eases permitting, these could move forward more quickly.
• Stable Cash Flows: The company relies heavily on fee-based contracts, offering insulation from commodity price volatility.

Outlook

• Near-Term: Growth could come from incremental expansions and higher throughput in core regions (Permian, Haynesville).
• Long-Term: Kinder Morgan’s wide moat in natural gas pipelines positions it well to capitalize on sustained LNG export growth.

---

2. Williams Companies (NYSE: WMB)

Company Snapshot

• Market Cap (Approx.): $35–40 billion
• Dividend Yield (Approx.): Around 5–6%
• Core Operations: Operates the Transco pipeline (spanning Texas to New York), plus major assets in the Marcellus/Utica.

Investment Thesis

• Strategic Marcellus Focus: Appalachia is the largest U.S. gas-producing region; increased drilling here directly impacts Williams’ throughput.
• Transco Pipeline Dominance: Critical infrastructure delivering gas to high-demand corridors on the East Coast; expansions regularly go online to meet regional and export needs.
• Stable, Regulated Cash Flows: Similar to Kinder Morgan, Williams benefits from fee-based or regulated rate structures.

Outlook

• Near-Term: Projects aimed at debottlenecking Appalachian supply could accelerate if permitting for expansions becomes more streamlined.
• Long-Term: Steady demand from high-density markets along Transco’s route, plus rising LNG exports via Gulf Coast terminals, supports robust throughput.

---

3. Energy Transfer LP (NYSE: ET)

Company Snapshot

• Market Cap (Approx.): $40–45 billion
• Distribution Yield (Approx.): 8–10%, often higher than peers
• Core Operations: Vast network of natural gas, natural gas liquids (NGLs), and crude oil pipelines, spanning multiple basins.

Investment Thesis

• Integrated System: Energy Transfer connects production basins (Permian, Marcellus, Utica, Bakken) to end markets, including significant processing and fractionation capacity.
• Growth-Oriented Management: Known for acquisitions (e.g., merging with Enable Midstream) and aggressive pipeline expansions. A friendlier federal stance on energy could support further growth.
• Attractive Yield: Distributions are typically higher than industry averages; potential volume growth could sustain or even increase payouts.

Outlook

• Near-Term: Ramping production in Permian and Haynesville could fill ET’s underutilized capacity and boost earnings.
• Long-Term: Additional NGL and crude expansions, plus possible synergy in new Gulf Coast export facilities, may drive continued growth.

---

4. Enterprise Products Partners (NYSE: EPD)

Company Snapshot

• Market Cap (Approx.): $55–60 billion
• Distribution Yield (Approx.): 7–8%
• Core Operations: Over 50,000 miles of pipelines, large NGL processing and fractionation footprint, plus export terminals.

Investment Thesis

• NGL Leader: Enterprise is a major mover of natural gas liquids, which often see increased production when natural gas and crude drilling climbs.
• Stable, Long-Term Contracts: A large portion of EPD’s revenue is secured through long-term agreements; less commodity price risk.
• Export Potential: Gulf Coast terminals (e.g., on the Houston Ship Channel) could see higher volumes if LNG and NGL exports expand.

Outlook

• Near-Term: Increases in associated gas and NGL output from the Permian may flow through EPD’s gathering and fractionation networks.
• Long-Term: Strong balance sheet and conservative financial management allow for steady expansions and reliable distributions.

---

5. ONEOK (NYSE: OKE)

Company Snapshot

• Market Cap (Approx.): $25–30 billion
• Dividend Yield (Approx.): 5–6%
• Core Operations: Gathering, processing, and transportation of natural gas and NGLs primarily in the Mid-Continent and Williston Basin.

Investment Thesis

• Strategic Basin Exposure: Positioned in the Bakken (Williston) and Mid-Continent (Oklahoma, Kansas) where natural gas and NGL production can surge under favorable drilling economics.
• Recent Expansion Moves: ONEOK’s acquisition of Magellan Midstream in 2023 broadened its asset base, diversifying the company’s commodity mix and expanding pipeline mileage.
• Fee-Based Revenue Model: A heavy reliance on fee-based contracts protects against commodity price downturns.

Outlook

• Near-Term: Heightened drilling in the Bakken could lift gas and NGL volumes for ONEOK’s gathering and processing systems.
• Long-Term: Integration of assets from the Magellan acquisition could improve economies of scale and support stable cash flows.

---

Risk Factors & Considerations

1. Permitting & Legal Challenges: Even with federal support, local and environmental litigation can delay major pipelines.
2. Commodity Price Swings: Sharp declines in oil or natural gas prices can slow upstream drilling, lowering volumes.
3. Interest Rate Environment: Higher rates raise the cost of capital for new infrastructure projects and can pressure distributions for high-yield MLPs.
4. Global Economic Shifts: If global LNG or oil demand softens, export-driven volume growth could underperform expectations.

---

Conclusion & Investment Implications

Under President Trump’s renewed emphasis on fossil fuel production, these five pipeline companies—Kinder Morgan, Williams, Energy Transfer, Enterprise Products Partners, and ONEOK—are well-positioned to capture incremental volume growth and capitalize on expedited infrastructure approvals. While each faces unique market and regulatory risks, their strategic asset footprints, stable fee-based contracts, and potential for heightened utilization present a favorable outlook for midstream investors over the next few years.

Final Note: Prospective investors should monitor evolving policy initiatives, global energy market trends, and company-specific updates (balance sheet strength, capital expenditure plans, distribution strategies) to make well-informed decisions.

ED Note:

With a heavy focus by the incoming administration on speeding up the advancement of Ai Tech, the energy sector benefits, especially those companies that will carry that energy to it's destinations!

We curenty have no positions in the companies mentioned however we are placing them on our watch list for now!

---

This report is provided for general information only and does not constitute a recommendation to buy or sell securities. Always conduct independent research or consult a financial advisor for personalized guidance.

Who might be interested in Acquiring Chargepoint's EV charging network?

How would an export tax levied by Canada on all it's natural resources entering the USA affect American business and society

Intellia Therapeutics newest breakthrough signals a bright future for treating serious hereditary conditions, offering profound implications for millions of patients worldwide.

 

Intellia Therapeutics is one of the leading companies at the forefront of developing in vivo (inside the body) CRISPR/Cas9 gene editing therapies. The company has drawn significant attention for its potential “single infusion” approach, wherein patients receive a one-time intravenous (IV) dose designed to edit or knock down the disease-causing gene directly in their cells. This is different from older or more traditional gene therapy methods, which often require multiple treatments or ex vivo manipulation (editing cells outside the body and re-infusing them).

Below is an expanded look at how Intellia’s technology works, why it is so promising, and what it could mean for patients with genetic diseases.

---

1. How Intellia’s CRISPR Therapy Works

A. CRISPR/Cas9 Mechanism

• CRISPR/Cas9 is a gene editing tool derived from bacterial defense systems.
• It relies on the Cas9 protein (an enzyme) to “cut” DNA at a precise site guided by a short piece of RNA (guide RNA).
• Once the DNA is cut, the cell’s natural repair mechanisms can either silence (knock out) or correct mutations in that gene.

B. Delivery via Lipid Nanoparticles (LNPs)

• Intellia packages the messenger RNA (mRNA) for both the Cas9 enzyme and the guide RNA (gRNA) inside lipid nanoparticles.
• Upon IV infusion, these nanoparticles circulate in the bloodstream and are taken up primarily by liver cells (hepatocytes).
• Once inside the cells, the mRNA is translated, producing the Cas9 enzyme and the gRNA. The gene-editing process begins, targeting the disease-causing gene.

C. Single Infusion Goal

• Because the CRISPR “cut” permanently modifies a portion of the genome in the target cells, it has the potential to create a durable effect.
• This is why a single IV infusion could be sufficient to significantly reduce or eliminate the production of a harmful protein—potentially for the life of the edited cell.

---

2. Key Programs and Data

A. NTLA-2001 for Transthyretin (TTR) Amyloidosis

One of Intellia’s most notable programs is NTLA-2001, aimed at treating transthyretin (TTR) amyloidosis. TTR amyloidosis occurs when the TTR protein misfolds and aggregates in tissues, leading to organ damage.

• Early Clinical Data:

  • Patients receiving a single infusion of NTLA-2001 showed a significant reduction—over 90% in some cohorts—of the problematic TTR protein in circulation.
  • This reduction could halt or slow the progression of the disease, potentially sparing patients from further organ damage.

• Significance:

  • These were some of the first compelling human data showing that you can edit a disease-causing gene inside the body (in vivo) with a single dose, creating a major milestone in gene therapy and CRISPR medicine.

B. NTLA-2002 for Hereditary Angioedema (HAE)

Another key therapy in Intellia’s pipeline is NTLA-2002, aimed at hereditary angioedema (HAE)—a genetic condition that causes severe, recurrent swelling episodes.

• Mechanism:

  • This therapy uses CRISPR/Cas9 to knock out a target gene in the liver that drives overproduction of certain proteins responsible for HAE symptoms.
  • A single IV infusion could be enough to offer long-term protection from these severe swelling attacks.

• Early Results:

  • Initial clinical data suggest robust reduction of the target protein with a favorable safety profile, reinforcing the concept that a single-dose CRISPR approach can be both powerful and potentially safe.

---

3. Potential Advantages of a “Single Infusion” Approach

Intellia CEO exited about one time treatment

1. Long-Term (Possibly Lifelong) Benefit

   • Traditional treatments for many genetic diseases require lifelong administration (e.g., enzyme replacement therapy, regular injections).
   • If CRISPR editing is durable over time, patients may only need one dose to substantially reduce their disease burden—this is a paradigm shift for chronic disease management.

2. Improved Quality of Life

   • Reducing or eliminating the need for repeated treatments not only lowers healthcare costs over time but also drastically improves convenience and quality of life for patients, who may not need frequent hospital visits or infusions.

3. Potential for True “Cure”

   • While “cure” is a strong word, the permanent genomic change holds the promise of halting disease processes at their genetic root.
   • If the edited cells maintain normal function (and pass down that corrected DNA through cell divisions), it could mean enduring remission or even reversal of disease symptoms.

4. Platform Approach

   • Once the single-infusion LNP platform is proven for one disease, it could be adapted to address many others by simply swapping the guide RNA sequence.
   • This versatility could accelerate the development of new gene therapies for a broader range of genetic disorders.

---

4. Challenges and Considerations

1. Safety and Off-Target Effects

   • CRISPR edits must be specific, because erroneous cuts could create new mutations or unintended consequences.
   • Early data are encouraging, showing minimal off-target editing, but longer-term studies are needed to confirm safety.

2. Durability Over Time

   • While initial reductions in disease-causing proteins are promising, it is important to track whether these edits remain stable and functional for months and years after treatment.

3. Immune Response to CRISPR Components

   • Any therapy introducing proteins or RNA into the body can trigger an immune response.
   • Careful dosing strategies and monitoring are essential to ensure patients tolerate the therapy.

4. Scaling Up Manufacturing

   • Lipid nanoparticle production and maintaining consistent quality at larger scales can be complex.
   • To serve more patients, the manufacturing process must be robust and standardized.

5. Regulatory Pathways and Cost

   • First-of-its-kind therapies often face regulatory hurdles as agencies carefully evaluate safety and efficacy data.
   • Single-dose cures or near-cures can be expensive up front, so there’s ongoing discussion around insurance, value-based pricing, and accessibility.

---

5. Outlook

Intellia’s success with in vivo CRISPR therapies—particularly the possibility of treating or potentially curing genetic conditions with a single IV infusion—represents a significant leap forward in precision medicine. As clinical trials expand and progress through later phases, more data will inform how safe, effective, and durable these therapies are over time. If these therapies continue to show positive outcomes, they could reshape the treatment landscape for many rare (and eventually more common) genetic diseases.

While challenges remain—especially around long-term safety, regulatory approvals, and equitable access—the overarching promise of a one-time dose that corrects a genetic defect at its source is nothing short of revolutionary. It signals a future in which treating serious hereditary conditions might be as straightforward as a short outpatient procedure, offering profound implications for millions of patients worldwide.

Related Articles:

Intellia Therapeutics has spent the past 10 years developing cutting edge genome editing technology to cure diseases

Three companies are leading the charge into Gene editing technology and medical advancements that seek to cure otherwise incurable diseases!

Including NTLA, we've been collecting these small cap biotech and healthcare stocks this year! Here's why!

Cutting-Edge Healthcare Advancements: 2025 Outlook

 

This report highlights eleven publicly traded companies at the forefront of medical innovation. Each organization is driving progress through breakthrough technologies—ranging from gene editing to advanced surgical systems—and is poised to enhance healthcare outcomes by 2025. While each company focuses on different aspects of healthcare, they share a common theme: leveraging innovation to improve patient care, reduce disease burden, and transform standards of practice.

---

1. Moderna (NASDAQ: MRNA)

Primary Focus: mRNA Vaccines & Therapeutics
Key Advancements:

• mRNA Platform Expansion: Known for its COVID-19 vaccine, Moderna is expanding mRNA-based treatments for cancer, rare genetic disorders, and various infectious diseases (e.g., influenza, RSV).
• Personalized Cancer Vaccines: Working on individualized cancer vaccines that prime the immune system to target tumor-specific antigens.
• 2025 Outlook:
  • Faster Vaccine Development Cycles: The proven modularity of mRNA platforms could enable rapid updates in response to emerging pathogens.
  • Broader Therapeutic Pipeline: If pivotal trials succeed, mRNA therapies may offer new standards of care for conditions lacking effective treatments.

---

2. CRISPR Therapeutics (NASDAQ: CRSP)

Primary Focus: Gene Editing (CRISPR-Cas9)
Key Advancements:

• Ex Vivo Gene Editing: Lead programs focus on correcting genetic mutations for beta thalassemia and sickle cell disease by editing patients’ cells outside the body.
• Oncology Pipeline: Investigating CRISPR-based therapies to engineer immune cells (e.g., CAR-T cells) that more effectively target cancers.
• 2025 Outlook:
  • Potential Curative Treatments: Pending regulatory approval, CRISPR-based therapies may become one-time cures for hereditary blood disorders.
  • Scalability & Access: Demonstrated success in initial indications may pave the way for broader use in other genetic conditions.

---

3. Editas Medicine (NASDAQ: EDIT)

Primary Focus: Gene Editing (CRISPR & Base Editing)
Key Advancements:

• In Vivo and Ex Vivo Editing: Developing CRISPR-based therapies for ocular diseases (e.g., Leber Congenital Amaurosis) and other rare genetic conditions.
• Base Editing Exploration: Investigating base-editing tools for precise, single-nucleotide modifications without creating double-stranded breaks.
• 2025 Outlook:
  • First-in-Human Ocular Gene Editing: Editas’s trials in vision restoration could transform the approach to inherited retinal diseases.
  • Expanding Applications: If initial programs prove safe and efficacious, base editing may target a wide range of genetic mutations with fewer off-target effects.

---

4. Intellia Therapeutics (NASDAQ: NTLA)

Primary Focus: In Vivo Gene Editing
Key Advancements:

• Transthyretin Amyloidosis (ATTR) Program: Showcased successful in vivo gene editing by delivering CRISPR directly to the liver.
• Broader Pipeline: Targeting other hereditary conditions such as hereditary angioedema and exploring oncology applications.
• 2025 Outlook:
  • Validated In Vivo Approach: Demonstrated clinical proof-of-concept could open doors to editing diseases at the source.
  • Streamlined Therapies: Potential single-dose treatments for chronic, life-limiting conditions, significantly improving patients’ quality of life.

---

5. Beam Therapeutics (NASDAQ: BEAM)

Primary Focus: Base Editing
Key Advancements:

• Precise Single-Base Changes: Beam’s platform edits just one “letter” of DNA, reducing the risk of large-scale genomic disruptions.
• Broad Pipeline Targets: Includes programs for cardiovascular, blood, liver, and ocular disorders, among others.
• 2025 Outlook:
  • Reduced Off-Target Effects: Base editing may offer safer alternatives to standard CRISPR approaches, which can cause double-stranded breaks.
  • Accelerated Clinical Trials: If Beam’s initial clinical programs show strong safety and efficacy, the technology could rapidly expand to treat a wide variety of monogenic disorders.

---

6. Illumina (NASDAQ: ILMN)

Primary Focus: Next-Generation Sequencing (NGS)
Key Advancements:

• High-Throughput Genome Sequencing: Illumina’s platforms power large-scale genetic research and clinical diagnostics.
• Cost Reduction & Accessibility: Continually driving down the cost per genome, making personalized medicine more feasible.
• 2025 Outlook:
  • Precision Medicine Standard: Routine genomic profiling in cancer, rare diseases, and newborn screening could become standard of care.
  • Population Genomics: Wider adoption in population health studies and preventive care, enabling earlier detection of risk factors and targeted interventions.

---

7. Intuitive Surgical (NASDAQ: ISRG)

Primary Focus: Robotic-Assisted Surgery
Key Advancements:

• da Vinci Surgical System: A robotic platform enabling greater surgical precision and minimal invasiveness.
• Expanded Surgical Applications: Ongoing R&D to extend robotic surgery into more complex procedures (e.g., thoracic, bariatric, and cardiac surgeries).
• 2025 Outlook:
  • Standardization of Robotic Surgery: As more hospitals adopt these systems, patients could experience fewer complications and shorter recovery times.
  • Improved Surgeon Training & Efficiency: Next-generation technologies, including virtual reality simulations, will further refine surgical outcomes.

---

8. Boston Scientific (NYSE: BSX)

Primary Focus: Medical Devices & Interventional Therapies
Key Advancements:

• Cardiovascular Innovations: Advanced stents, ablation catheters, and heart failure devices.
• Neuromodulation & Urology: Devices like spinal cord stimulators, deep brain stimulation, and minimally invasive urology solutions.
• 2025 Outlook:
  • AI & Diagnostics Integration: Incorporating data analytics and AI into device monitoring to offer more personalized patient care.
  • Less Invasive Procedures: Continued shift from open surgeries to minimally invasive interventions, reducing hospital stays and improving outcomes.

---

9. Dexcom (NASDAQ: DXCM)

Primary Focus: Continuous Glucose Monitoring (CGM) Systems
Key Advancements:

• Real-Time Glucose Tracking: Sensors that automatically measure and transmit glucose data every few minutes.
• Data Integration: Partnerships with insulin pump manufacturers and smartphone apps for closed-loop insulin delivery.
• 2025 Outlook:
  • Closed-Loop Systems: Move toward “artificial pancreas” solutions where insulin delivery is automated, significantly reducing diabetes complications.
  • Improved Accuracy & Comfort: Next-generation CGMs may have longer wear times and less invasive sensor designs, further enhancing adoption.

---

10. Medtronic (NYSE: MDT)

Primary Focus: Broad Medical Devices & Connected Health
Key Advancements:

• Cardiac & Vascular Devices: State-of-the-art pacemakers, defibrillators, and heart-valve repair systems.
• Diabetes Management: Insulin pumps and continuous glucose monitoring integrations.
• AI-Driven Platforms: Remote monitoring solutions and predictive analytics to manage chronic conditions.
• 2025 Outlook:
  • Personalized Medicine at Scale: Leveraging data from implanted devices to tailor therapies in real time.
  • Reducing Readmissions: Better remote monitoring can catch complications earlier, lowering costs and improving patient outcomes.

---

11. Edwards Lifesciences (NYSE: EW)

Primary Focus: Structural Heart & Critical Care Monitoring
Key Advancements:

• Transcatheter Aortic Valve Replacement (TAVR): Minimally invasive heart valve therapies that reduce surgical risk.
• Critical Care Monitoring: Advanced hemodynamic monitoring systems guiding clinical decision-making in ICU settings.
• 2025 Outlook:
  • Mainstream TAVR Adoption: As the technology evolves, more patient populations (including lower-risk groups) may qualify for transcatheter procedures, reducing the need for open heart surgery.
  • Improved Post-Operative Outcomes: Next-generation devices and monitoring capabilities will further enhance patient recovery and long-term cardiac health.

---

Conclusion

These eleven companies are leading a transformative era in healthcare. Collectively, they are:

• Rewriting the Genetic Code: Gene editing and base editing promise curative approaches for diseases once considered incurable.
• Reinventing Treatment Modalities: mRNA vaccines, targeted therapies, and minimally invasive surgical devices are refining standards of care.
• Elevating Patient Monitoring & Management: Continuous glucose monitoring, AI-driven diagnostics, and remote device integrations enable proactive, personalized care.
• Driving Down Costs & Hospitalizations: Less invasive procedures, early detection, and potential “one-time” curative treatments can significantly reduce healthcare expenditures over time.

By 2025, the interplay of these innovations—and the data they generate—has the potential to significantly enhance patient outcomes, streamline clinical workflows, and move us closer to a future where healthcare is predictive, preventive, and precisely tailored to individual patient needs.

ED Notes:

We have invested in 3 of these companies and placed the others on our watch list!

Royalty Pharma (NASDAQ: RPRX) is our Healthcare "Anchor Stock"!

What's up with UiPath, it's Robotics Automation and it's recent push into healthcare?

"NASH" is a serious healthcare problem and it is one important reason why Viking Therapeutics might become a takeover target!

 

Viking Therapeutics (NASDAQ: VKTX)

Viking Therapeutics is a clinical-stage biopharmaceutical company focused primarily on the development of therapies for metabolic and endocrine-related disorders. Founded in 2012, Viking has since concentrated on conditions such as nonalcoholic steatohepatitis (NASH), dyslipidemia (abnormal blood lipids), and certain rare disorders.

Below is a high-level summary regarding its viability and intellectual property.

---

1. Company Viability

Clinical Pipeline

• VK2809 (Thyroid Receptor Beta Agonist):
  Viking’s lead candidate, VK2809, is an orally administered, liver-selective thyroid receptor beta agonist. The drug is being studied for the treatment of NASH and hypercholesterolemia. Positive interim clinical data have shown promising improvements in liver fat reduction and cholesterol management, key endpoints for NASH and dyslipidemia.

• VK0214 (Thyroid Receptor Beta Agonist):
  Another asset in Viking’s portfolio, VK0214, also targets thyroid receptor beta but is being evaluated in a rare condition known as X-linked adrenoleukodystrophy (X-ALD). Early studies suggest potential benefits in reducing very long-chain fatty acids (VLCFAs), which are implicated in X-ALD.

• VK5211 (Selective Androgen Receptor Modulator – SARM):
  Viking also has an investigational SARM for muscle-wasting conditions, although recent focus has been more on VK2809 and VK0214.

Financial and Operational Health

• R&D Focus: As a clinical-stage company, Viking Therapeutics does not generate revenue through commercialized products. Instead, it relies on external funding (equity financing, licensing deals, etc.) to drive its research.
• Partnerships and Collaborations: While not as partnership-heavy as some larger pharmaceutical companies, Viking has drawn industry attention, especially regarding positive NASH data. This can lead to potential partnering opportunities in the future.
• Viability: The company’s viability hinges on advancing its lead candidates successfully through clinical trials. Positive early- and mid-stage results have made Viking a notable player in the NASH space, which is highly competitive but also has significant commercial potential.

Given Viking’s progress, the market generally views it as a legitimate contender in the metabolic and endocrine disorder therapeutic space. That said, clinical-stage companies still face the inherent uncertainty of drug development risks (trial failures, regulatory hurdles, funding shortfalls, etc.).

---

2. Patents and Proprietary Technology

Patent Portfolio

• Drug-Specific Patents: Viking Therapeutics holds patents and has filed patent applications covering the composition of matter and/or methods of use for its drug candidates (VK2809, VK0214, VK5211). Composition-of-matter patents generally provide strong protection because they cover the chemical structure of the drug itself.
  
  
  
• Method-of-Use Patents: These can protect the specific ways in which Viking’s drug candidates are used to treat certain diseases or patient populations.

These patents are crucial for a biopharmaceutical company:

1. Exclusivity: They offer legal exclusivity that can help protect the company from generic competition if/when a drug is approved.
2. Commercial Value: Strong patent protection can attract partnerships and licensing deals, providing potential sources of capital.

3. Why This Matters

Addressing Large Unmet Needs

• NASH: A growing prevalence of NASH has resulted in significant healthcare expenditures. If VK2809 proves effective, it could become a leading treatment in a multibillion-dollar market.
• X-ALD: This is a rare but serious genetic condition lacking many good therapeutic options; VK0214 has the potential to fill that gap if successful.

Potential for Market Impact

• Commercialization Prospects: Should any of Viking’s programs gain FDA approval, the resulting therapies could potentially reshape the treatment landscape for their respective indications.
• Investor/Industry Interest: Positive trial results and new patents often draw investor interest, collaborations, and licensing deals, which in turn help fund future research and development.

---

Conclusion

Viking Therapeutics (NASDAQ: VKTX) is a legitimate clinical-stage biopharmaceutical company focusing on metabolic and endocrine disorders, a space with substantial medical need and commercial potential. It holds (and continues to seek) patents around its lead compounds—most notably its liver-selective thyroid receptor beta agonists—that protect the composition and therapeutic use of its drug candidates.

While it is premature to label Viking’s technologies as “vital” to the entire healthcare industry before late-stage clinical success and regulatory approvals, the company’s pipeline could become highly important if it successfully brings novel treatments to market for NASH, X-ALD, and other conditions. Overall, Viking is considered a “viable” biotechnology player insofar as it remains well-funded, demonstrates promising early clinical results, and continues to progress its candidates through the R&D pipeline.

---

NASH (Nonalcoholic Steatohepatitis) is an advanced form of nonalcoholic fatty liver disease (NAFLD). It occurs when excess fat builds up in the liver, causing inflammation and liver cell damage. Over time, NASH can progress to more severe conditions, including cirrhosis (scarring of the liver), liver failure, or even liver cancer. Unlike alcoholic liver disease, NASH develops in people who drink little or no alcohol.

Why is NASH Important in This Context?

1. Growing Prevalence: As rates of obesity, diabetes, and metabolic syndrome increase worldwide, so does the incidence of NAFLD and NASH. Some experts project that NASH could become the leading cause of liver transplants in the near future.

2. Lack of Approved Therapies: Despite the significant disease burden, there are currently no broadly approved medications specifically indicated for NASH. This gap creates a major unmet medical need, prompting numerous biopharmaceutical companies—like Viking Therapeutics—to develop novel treatments.

3. Large Market Opportunity: Because NASH can be life-threatening if it progresses, and because millions of people worldwide may be living with undiagnosed or untreated NASH, a successful therapy could be both medically transformative and commercially significant.

4. Focus of Viking Therapeutics: Viking’s lead candidate, VK2809, is being developed to target this condition by reducing liver fat and improving metabolic parameters. Positive data in NASH trials could position Viking (and similar companies) as key players in an increasingly important sector of the healthcare industry.

In summary, NASH is central to the discussion about Viking Therapeutics because it represents a substantial unmet need in medicine and a potentially large market, making it a prime target for biopharmaceutical innovation.

Potential Takeover Appeal of Viking Therapeutics

Because Viking Therapeutics is pursuing novel treatments in a high-demand area (particularly NASH), it naturally could draw interest from larger pharmaceutical or biotechnology companies looking to expand their metabolic and liver disease portfolios. Here are some factors making Viking Therapeutics a potential takeover target:

1. High-Unmet-Need Indication (NASH): With no widely approved therapies for NASH and a growing global patient population, companies recognize the potential of this market. An effective NASH therapy could generate significant revenue, making any promising pipeline a tempting acquisition.

2. Promising Pipeline Data: Viking’s lead candidate, VK2809, has shown encouraging early- and mid-stage clinical results. If later trials continue to demonstrate efficacy and safety, it could sharply increase interest from potential acquirers who value de-risked assets.

3. Focused Portfolio and Manageable Size: Acquiring a smaller, clinical-stage company can often be less risky (and less expensive) than attempting to build the same pipeline internally, especially if the candidate is already well-advanced in development.

---

Which Companies Might Be Suitors?

Given the strategic interest in NASH and related metabolic disorders, several categories of potential acquirers exist:

1. Large Pharma with Metabolic Focus:

   • Novo Nordisk: Already a major player in metabolic conditions (especially diabetes and obesity), Novo Nordisk has also shown interest in adjacent liver disorders.
   • Eli Lilly: Similar to Novo, Lilly’s diabetes and obesity franchises could benefit from a complementary NASH therapy.
   • AstraZeneca: Has a growing metabolic disease portfolio; acquiring a late-stage NASH program could expand their pipeline rapidly.

2. Companies Already Investing Heavily in NASH:

   • Gilead Sciences: Has multiple ongoing NASH programs (e.g., selonsertib in the past, firsocostat, etc.). While some programs have faced setbacks, Gilead’s interest in finding a strong NASH asset remains high.
   • Intercept Pharmaceuticals: Intercept’s obeticholic acid (OCA) program in NASH has been under FDA review and scrutiny; a complementary or alternative mechanism like VK2809 might be appealing (though Intercept’s own position has fluctuated).

3. Larger Biotech Firms Expanding Their Pipeline:

   • Amgen, Merck, Pfizer, or Bristol Myers Squibb (BMS) all maintain broad portfolios and often look to “bolt on” promising late-stage assets. If data readouts continue to be positive and the market opportunity for NASH remains robust, these big players could consider a strategic acquisition.

4. Regional Pharmaceutical Companies:
   In some cases, companies based in Asia or Europe—less prominent in the U.S. but eager to expand—may seek external NASH candidates to bring to their domestic markets.

---

Key Considerations

• Clinical Data Maturity: Large pharmaceutical companies typically prefer to acquire assets that have demonstrated clear efficacy in Phase 2 or later. Viking’s value as a target will likely hinge on strong data from mid- to late-stage trials.
• Competitive Landscape: Multiple biopharma firms are racing to develop NASH treatments, and some may have safer or more efficacious molecules. The better Viking’s data looks compared to competitors, the higher the interest from suitors.
• Valuation & Partnering vs. Acquisition: Viking could opt for licensing agreements or strategic collaborations rather than a full sale, especially if management believes the asset’s value will continue to grow. A partnership often allows a smaller biotech to retain some rights and revenue streams if the drug is approved.

---

Conclusion
While no acquisition is guaranteed, Viking Therapeutics’ focus on a high-impact condition with robust commercial potential makes it a plausible takeover candidate—particularly if ongoing trials continue to post encouraging results. Large pharma players with existing metabolic franchises (e.g., Novo Nordisk, Eli Lilly) or those already investing in NASH (e.g., Gilead Sciences) are often cited as the most likely suitors. Ultimately, further clinical success for VK2809 (and the rest of Viking’s pipeline) will be the key factor in whether such a transaction emerges.

An informed “guess” as to which three companies might be most inclined to take a serious look at Viking Therapeutics (assuming continued positive data for VK2809 and the rest of its pipeline), they would be:

1. Novo Nordisk

   • Why? Novo Nordisk is a leading force in metabolic diseases (diabetes, obesity) and has already shown interest in expanding its pipeline into adjacent liver and metabolic conditions. NASH treatment could complement their GLP-1 franchise and semaglutide research.

2. Eli Lilly

   • Why? Lilly is also heavily invested in diabetes and obesity with growing success (for instance, tirzepatide). Acquiring a promising NASH asset could further bolster their metabolic portfolio, leveraging existing commercial channels for related conditions.

3. Gilead Sciences

   • Why? Gilead was an early mover in NASH and has made multiple bets in the space (though some faced challenges). They still have a vested interest in finding a successful NASH therapy, and a proven or promising clinical candidate (like VK2809) could be a natural fit.

Ultimately, any large pharma with strategic interest in metabolic or liver diseases could be a contender, but these three often come up in speculative discussions due to their deep metabolic pipelines, established commercial infrastructure, and ongoing focus on NASH.

Disclaimer: This information is provided for general informational purposes and does not constitute financial or medical advice. If you are considering any investment or therapeutic decisions, it is advisable to consult with professional advisors.

ED Note:

We currently have no position in VKTX, however we are placing it on our watch list!

Update: Jan 29th - We have now purchased shares of VKTX

Cutting-Edge Healthcare Advancements: 2025 Outlook

Quantum technology is coming for all data! Who will be protecting Governments and enterprises from the quantum security threat?

 

The focus on quantum-safe algorithms and software solutions is a major area of research and development, driven by the looming threat of quantum computers breaking traditional cryptographic protocols. Several companies and organizations are leading the way in developing quantum-safe solutions. Here's a list of key players:

---

1. IBM

• Activities: IBM is a pioneer in quantum computing and quantum-safe cryptography. Their quantum-safe algorithms are designed to integrate with hybrid classical-quantum systems to secure data for the future.
• Products: IBM offers quantum-safe cryptographic solutions via their tools like IBM Quantum Safe and contributions to the National Institute of Standards and Technology (NIST) standardization process.

---

2. Google (Alphabet)

• Activities: Through its quantum computing efforts at Google Quantum AI, the company also researches quantum-resistant algorithms, particularly in partnership with academia.
• Initiatives: Contributions to post-quantum cryptography standards and experimenting with lattice-based cryptographic techniques.

---

3. Microsoft

• Activities: Microsoft’s Quantum Development Kit incorporates quantum-safe security measures, and they have been actively participating in developing post-quantum cryptographic solutions.
• Programs: Microsoft is investing heavily in quantum-safe algorithms through their Azure Quantum platform and collaborations.

---

4. Post-Quantum

• Activities: This UK-based company is focused entirely on post-quantum cryptography.
• Clients: They work closely with governments and defense organizations, including the UK’s National Cyber Security Centre (NCSC).
• Technology: They offer quantum-safe VPNs, encryption solutions, and integrate with existing infrastructures.

---

5. ISARA Corporation

• Activities: Based in Canada, ISARA specializes in quantum-safe cryptographic solutions and tools.
• Products: They offer tools like ISARA Catalyst for transitioning to post-quantum cryptography without disrupting existing systems.
• Focus Areas: Strong focus on public sector and enterprise customers.

---

6. Quantinuum (a collaboration between Honeywell and Cambridge Quantum)

• Activities: Focuses on integrating quantum-safe cryptography with quantum hardware and software platforms.
• Products: Their cybersecurity products, like Quantum Origin, offer quantum-enhanced key generation for enhanced security.

---

7. Arqit Quantum

• Activities: Arqit provides software-based encryption for quantum-safe communications.
• Products: Their flagship product, QuantumCloud, is designed to secure sensitive data for governments and enterprises.

---

8. NCC Group

• Activities: A global cybersecurity firm actively involved in quantum-safe cryptography development.
• Focus Areas: They provide consulting and technical services for businesses transitioning to post-quantum security measures.

---

9. Cybersecurity Startups

Several smaller but innovative startups are also leading efforts in this field:

• PQShield: Focused on hardware and software solutions for post-quantum security.
• Crypta Labs: Develops quantum-secure encryption solutions for IoT devices.
• QuintessenceLabs: Provides quantum-safe key management systems using quantum random number generators.

---

10. NIST-Backed Collaborators

• NIST's Post-Quantum Cryptography Standardization Project has identified CRYSTALS-Kyber and CRYSTALS-Dilithium as key algorithms for quantum-safe encryption. Companies contributing to and adopting these standards include:
  • Amazon Web Services (AWS)
  • Intel
  • Cisco

---

Industries Impacted

• Government & Defense: Secure communications and critical infrastructure protection.
• Financial Institutions: Quantum-safe cryptography for secure transactions.
• Healthcare & Biotech: Protecting sensitive medical records and proprietary research.

These companies are heavily investing in R&D to ensure their solutions meet the post-quantum security standards, while also aiming to integrate smoothly with legacy systems. The ongoing NIST standardization efforts provide a benchmark for their success.

Here are three companies currently providing enterprises and/or governments with quantum-safe software solutions for protecting sensitive data:

---

1. Arqit Quantum

• Software: QuantumCloud™ provides quantum-safe encryption to enterprises and governments.
• Usage:
  • Arqit works with NATO and allied governments to secure sensitive communications.
  • The platform allows customers to create quantum-safe encryption keys globally on demand.
• Applications: Focuses on defense, finance, and telecommunications sectors.
• Client Examples: Collaborates with U.S. and UK defense organizations, as well as private enterprises in critical sectors.

---

2. Post-Quantum

• Software: Offers quantum-safe encryption solutions, including post-quantum VPNs and integration tools for existing infrastructures.
• Usage:
  • Works directly with government bodies, including the UK's National Cyber Security Centre (NCSC).
  • Provides software solutions to secure national defense communications and critical infrastructure.
• Applications: Defense, critical national infrastructure, and enterprise systems.
• Client Examples: Trusted by national governments for secure post-quantum cryptography integration.

---

3. Quantinuum

• Software: Quantum Origin, a quantum-safe cryptographic key generation platform.
• Usage:
  • Delivers quantum-safe encryption keys to enterprises and governments.
  • Used to secure data in sectors like banking, telecommunications, and critical infrastructure.
• Applications: Provides enhanced security for public key infrastructure (PKI), ensuring data remains secure against future quantum attacks.
• Client Examples: Partners with governments and financial institutions globally.

---

These companies are actively working with both public sector and enterprise clients to ensure their data remains secure in the post-quantum era. Their products are not only in use but are also being scaled to meet future demand as quantum computing threats become more imminent.

Only one of these companies is currently publicly traded:

---

1. Arqit Quantum

Currently the only public pure play

• Status: Publicly Traded
• Ticker Symbol: ARQQ (NASDAQ)
• Details: Arqit Quantum became public via a SPAC merger in 2021. It is actively traded on the NASDAQ and focuses on quantum-safe encryption for governments and enterprises.

---

2. Post-Quantum

• Status: Private Company
• Details: Post-Quantum is a UK-based private company that specializes in post-quantum cryptography. It works with organizations like the UK’s National Cyber Security Centre (NCSC) and other government entities. It has raised private funding but has not gone public.

---

3. Quantinuum

• Status: Private Company
• Ownership: Quantinuum is a joint venture between Honeywell and Cambridge Quantum.
• Details: While it is private, it benefits from the backing of Honeywell, a publicly traded company (ticker: HON), which owns a majority stake.

---

ED note: 

We currently own Google! We have placed ARQQ on our watch list!

Related articles:

As the necessity for Quantum Communication grows, there is one microcap company that may become a crucial acquisition target!

Will Super Intelligent Machines Demote Us to the Level of Chimps, Maybe Even Poultry in the Realm of Intelligence?

Did we just witness the first actual building blocks of a future Quantum Internet?

Enovix knows full well that a world of EVs, Automation, Robotics and energy storage, will require millions of batteries!

ENVX battery manufacturing plants

Enovix is ramping up production of it's new batteries, hiring top experts and hinting at a possible partnership with Apple!

 

Enovix Corp (ENVX) – Updated Business Report (January 2025)

---

1. Introduction

Enovix Corporation (NASDAQ: ENVX) has continued to garner attention in the energy storage sector with its disruptive 3D silicon-anode lithium-ion battery architecture. Since its public listing in 2021 and subsequent production milestones reached in 2023 and 2024, Enovix has moved aggressively toward commercializing its unique battery design for consumer electronics, electric vehicles (EVs), and, increasingly, robotics applications. This report incorporates the most recent updates on Enovix’s technology developments, manufacturing capacity expansions, and potential collaborations with major companies—particularly Apple—while evaluating the broader outlook for Enovix’s role in a rapidly electrifying world.

---

2. Recent Technology and Product Advancements

1. 3D Silicon-Anode Architecture

   
   
   
   • Enovix’s core innovation remains its patented 3D architecture, which integrates a 100% active silicon anode. This design reportedly provides up to 30–40% higher energy density compared to standard lithium-ion batteries using graphite anodes.
   • Ongoing research since late 2023 focuses on enhancing cycle life and fast-charging capabilities. Recent internal testing shows improvements in maintaining high capacity retention over extended charge-discharge cycles—crucial for consumer electronics and potential EV applications.
     
     
     
     

2. Advanced Safety and Thermal Management

   • Enovix continues to emphasize safety features, including containment structures designed to mitigate thermal runaway.
   • Improved thermal management has positioned Enovix as a contender in applications where battery integrity under stress (e.g., drones, robotics, automotive) is paramount.

3. Fast-Charging Improvements

   
                                          Enovix boasts EV fast charging in 10 minutes!
   • As of Q4 2024, Enovix claims faster charge rates without sacrificing battery life. This is especially relevant for smartphones, wearable devices, and other consumer electronics where fast recharging is a key competitive advantage.
4. 
   
5. 
   

---

3. Manufacturing and Production Expansion

1. Fab-1 (Fremont, California)

   
   • Enovix’s first manufacturing line in Fremont has transitioned from pilot-scale to low-volume commercial production. Yield rates have gradually increased due to process refinements and equipment upgrades throughout 2024.
   • Recent guidance indicates that Fremont’s facility throughput has reached steady-state operations, paving the way for higher-volume output in 2025.

2. 
   • Fab-2 (Global Expansion Plans)
   • Enovix new “Fab-2” manufacturing plant, is being constructed at this writing in Penang, Malaysia, selected for supply-chain advantages and proximity to major consumer electronics manufacturers, with a target to begin pilot production in 2026.

3. Automation and Process Innovations

   
   
   
   • The company continues to invest heavily in manufacturing automation, aiming to reduce defect rates and streamline operations. This push is critical for bringing down costs and meeting large-scale consumer electronics demands.

---

4. Potential Partnerships and Client Landscape

1. Apple

   
   
   
   • Rumored Collaboration: Market analysts and media outlets have repeatedly speculated on Apple’s interest in Enovix’s next-generation batteries to power future devices—particularly iPhones, iPads, and possibly the rumored AR/VR headsets.
   • Technological Fit: Apple’s emphasis on device battery life, fast charging, and safety aligns closely with Enovix’s product value proposition.
   • Probability of Partnership: While no formal agreement has been announced, multiple industry sources suggest that Apple has evaluated or is in the process of evaluating Enovix battery samples. 
   • The probability of a multi-year supply agreement remains speculative but is generally viewed as credible given Apple’s tendency to source cutting-edge battery technology for its flagship devices. If a deal materializes, it could significantly boost Enovix’s revenue and market credibility.

2. Other Consumer Electronics OEMs

   • Enovix has sampled batteries to several Tier-1 and Tier-2 consumer electronics manufacturers in Asia. Initial feedback and pilot tests have reportedly been positive.
   • Partnerships could extend beyond smartphones to wearable devices, laptops, and other portable electronics where high energy density and safety are critical.

3. Emerging EV and Robotics Segments

   
   
   
   • While consumer electronics remains the near-term commercial priority, Enovix is also in preliminary discussions with automotive Tier-1 suppliers to explore potential adoption in electric vehicles (especially for specialized packs or range extenders).
     
     
     
   • Robotics and drone manufacturers have also expressed interest in Enovix’s high energy density batteries. The improved power-to-weight ratio is particularly attractive for autonomous systems, aerial drones, and industrial robots.

---

5. Financial Health and Recent Performance

1. Revenue Trajectory

   • Early sales from pilot-scale production and sample shipments contributed to modest revenues in 2023. According to Q3/Q4 2024 disclosures, revenues have begun to accelerate as the company onboards additional customers for low-volume orders.
   • The bulk of revenue growth is still anticipated from major supply agreements, pending successful qualification with top-tier OEMs.

2. Capital Expenditure and Funding

   • Enovix secured additional funding in early 2024 through a combination of equity offerings and strategic investments. This infusion supports ramp-up expenses for Fab-1 and the initial groundwork for Fab-2.
   • The company’s balance sheet remains relatively strong, with cash reserves earmarked for scaling production and further R&D.

3. Stock Performance

   • ENVX has experienced volatility, reflecting broader market swings in the tech and EV/battery sectors. Positive announcements about pilot trials or large-scale supply contracts often catalyze stock price gains.
   • Analysts generally maintain a cautiously optimistic outlook, citing Enovix’s unique technology advantage but also acknowledging the execution risks common to capital-intensive hardware startups.

---

6. Outlook in a World of EVs, Robotics, and Beyond

1. Consumer Electronics Dominance

   • The most immediate commercial success for Enovix is likely in smartphones, laptops, wearable devices, and other portable gadgets that benefit from lighter, longer-lasting batteries.
   • If Apple—or another major OEM—signs a large-scale supply contract, Enovix’s technology could quickly become a market reference point for high-energy, safe batteries.

2. Growing EV Opportunities

   • EVs represent a massive market opportunity. Though Enovix’s initial focus has been consumer electronics, improvements in silicon anode longevity and scale-up manufacturing could position the company to address specialized EV battery applications.
   • Partnerships or joint ventures with established automotive suppliers may help Enovix navigate the complexity and certification requirements of the automotive industry.

3. Robotics, Drones, and Industrial Applications

   • The increasing electrification of robotics (both commercial and industrial) presents another long-term growth avenue. High energy density and robust safety features are major selling points for powering autonomous systems.
   • Drone manufacturers, in particular, require high power-to-weight ratios for longer flight times—an area where Enovix’s technology excels.

4. Competitive and Regulatory Landscape

   • Other battery startups and established players (e.g., QuantumScape, Solid Power, LG Energy Solution, Samsung SDI) are investing heavily in next-gen battery solutions, including solid-state technology.
   • Regulatory push for greener energy solutions, along with government incentives for battery manufacturing, could bolster Enovix’s expansion plans. However, it also intensifies competition as more players vie for subsidies and market share.

---

7. Key Risks and Considerations

1. Manufacturing Scale-up Risks
   • Transitioning from pilot to mass production remains a significant operational challenge. Any delay or yield issue could push back deliveries and affect financial performance.
2. Supply Chain and Material Constraints
   • Silicon-based anodes require specialized materials and process controls. Global disruptions or shortages of critical materials could impact cost and production schedules.
3. Customer Adoption Timelines
   • Large OEMs often have lengthy qualification and testing cycles. Even if Enovix’s technology is promising, converting pilot evaluations to full commercial contracts can take several product cycles.
4. Competitive Pressure
   • The battery sector is highly competitive, with numerous companies pursuing advanced lithium-ion or solid-state solutions. Enovix must maintain technology and cost advantages to stand out.

---

8. Conclusion

Enovix stands at the forefront of next-generation lithium-ion battery technology, with its 3D silicon-anode architecture showing strong potential to reshape the landscape of consumer electronics, EVs, and robotics. The company’s manufacturing ramp in Fremont and planned global expansion signal that it is transitioning from technology innovator to commercial player.

Why It May Be a Good Investment in Early 2025:

With Fab-1 now producing commercial volumes and Fab-2 in the pipeline, Enovix is positioned to capitalize on growing demand for higher energy density batteries. Ongoing talks with major OEMs (including the possibility of a high-profile partnership with Apple), continued market interest in EV and robotics solutions, and a strong balance sheet provide a compelling growth story. While there are always risks in scaling and delivering at high volume, Enovix’s unique technology advantage in a rapidly expanding market suggests that the company could deliver outsized returns to early shareholders in 2025 and beyond.

Should Enovix execute effectively, it could emerge as a leading supplier of advanced lithium-ion batteries, shaping the next generation of consumer devices, electric vehicles, and robotic applications worldwide.

---

Disclaimer:
This report is based on publicly available information and industry insights as of January 2025. It is provided for informational purposes and should not be construed as financial or investment advice. Prospective investors and stakeholders are encouraged to conduct their own due diligence and consult professional advisors before making any decisions related to Enovix Corporation.

Related Articles:

Enovix is ramping up production of it's new batteries, hiring top experts and hinting at a possible partnership with Apple!